Overall, this study presented a significant model for high risk of death and poor OS for patients with stage III NSCLC with relapse and distant metastases, non-responsive to platinum-based chemotherapy and EGFR TKIs, and harboring EGFR uncommon mutations, TP53 mutations, and EGFR/TP53 co-mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.